ORTX News and Press, Orchard Therapeutics plc From 10/22/20

BOSTON and LONDON, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company’s chief executive officer, Bobby Gaspar, M.D., Ph.D., has been appointed to the Alliance for Regenerative Medicine&#...

Gainers: ReWalk Robotics (RWLK) +18%, Aldeyra Therapeutics (ALDX) +19%, ClearPoint Neuro (CLPT) +15%, ProPhase Labs (PRPH) +12%, Orchard Therapeutics (ORTX) +11%.Losers: Biomerica (BMRA) -20%, Adaptimmune Therapeutics (ADAP) -14%, Ca...

Orchard Therapeutics (ORTX) 11% in premarket on moderate volume, after a positive CHMP opinion recommending approval of Libmeldy, an investigational gene therapy for the treatment of metachromatic leukodystrophy ((MLD)), a rare genetic condition caused by mutations in the ...

First therapy recommended for full marketing authorization in the EU for eligible patients with confirmed diagnosis of late infantile or early juvenile MLD variants One-time treatment with Libmeldy has been shown to preserve cognitive and motor function in most patients ...

Some gene therapy stocks including ORTX, QURE and RGNX are trading considerably lower than in January of 2020. ORTX, QURE and RGNX have all had issues unique to their businesses which may explain the depressed share prices. Recently, the FDA has taken a tougher stance on gene ther...

Four not-widely-followed biotech stocks were pitched at the recent Ira Sohn conference. Below is the full audio of the pitches, and a list of the publicly-traded landscape for each. For further details see: These Are The Four Biotech Stocks Recently Pitched At The Ira Sohn Conference

The European Medicines Agency ((EMA)) has granted Priority Medicines ((PRIME)) designation to Orchard Therapeutics' (ORTX) OTL-203, an ex vivo autologous hematopoietic stem cell ((HSC)) gene therapy in development for the treatment of mucopolysaccharidosis type I (MPS-I).M...

BOSTON and LONDON, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to OTL-203, an investigational ex vivo autologous hem...

Silence Therapeutics ( OTCPK:SLNCF ) appoints  Mark Rothera as President and CEO, effective immediately. More news on: Orchard Therapeutics plc, Silence Therapeutics plc, Healthcare stocks news, Read more ...

BOSTON and LONDON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company is scheduled to present at the following virtual investor conferences in September: Morgan Stanley 18th Annual Global Healthcare Conf...